Key Points

  • CAR22 therapy induced complete remission in 3 patients with LBCL who had relapsed after CAR19 therapy and caused no severe toxicities.

Abstract

The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first 3 consecutive patients with autologous CAR19-refractory LBCL who were treated with a single infusion of autologous 1 × 106 CAR+ T cells per kilogram targeting CD22 (CAR22) as part of a phase 1 dose-escalation study. CAR22 therapy was relatively well tolerated, without any observed nonhematologic adverse events higher than grade 2. After infusion, all 3 patients achieved complete remission, with all responses continuing at the time of last follow-up (mean, 7.8 months; range, 6-9.3). Circulating CAR22 cells demonstrated robust expansion (peak range, 85.4-350 cells per microliter), and persisted beyond 3 months in all patients with continued radiographic responses and corresponding decreases in circulating tumor DNA beyond 6 months after infusion. Further accrual at a higher dose level in this phase 1 dose-escalation study is ongoing and will explore the role of this therapy in patients in whom prior CAR T-cell therapies have failed. This trial is registered on clinicaltrials.gov as #NCT04088890.

REFERENCES

1.
Spiegel
JY
,
Dahiya
S
,
Jain
MD
, et al
.
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy [published online ahead of print 6 November 2020]
.
Blood
. doi:10.1182/blood.2020006245.
2.
Neelapu
SS
,
Rossi
JM
,
Jacobson
CA
, et al
.
CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel [abstract]
.
Blood
.
2019
;
134
(
suppl 1
). Abstract 203.
3.
Boyd
SD
,
Natkunam
Y
,
Allen
JR
,
Warnke
RA
.
Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results
.
Appl Immunohistochem Mol Morphol
.
2013
;
21
(
2
):
116
-
131
.
4.
Majzner
RG
,
Rietberg
SP
,
Sotillo
E
, et al
.
Tuning the Antigen Density Requirement for CAR T-cell Activity
.
Cancer Discov
.
2020
;
10
(
5
):
702
-
723
.
5.
Fry
TJ
,
Shah
NN
,
Orentas
RJ
, et al
.
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
.
Nat Med
.
2018
;
24
(
1
):
20
-
28
.
6.
Shah
NN
,
Highfill
SL
,
Shalabi
H
, et al
.
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
.
J Clin Oncol
.
2020
;
38
(
17
):
1938
-
1950
.
7.
Shalabi
H
,
Kraft
IL
,
Wang
H-W
, et al
.
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
.
Haematologica
.
2018
;
103
(
5
):
e215
-
e218
.
8.
Huang
C
,
Zhang
H-C
,
Ho
J-Y
, et al
.
Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report
.
Oncol Lett
.
2020
;
20
(
4
):
21
.
9.
Lee
DW
,
Santomasso
BD
,
Locke
FL
, et al
.
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
.
Biol Blood Marrow Transplant
.
2019
;
25
(
4
):
625
-
638
.
10.
Cheson
BD
,
Fisher
RI
,
Barrington
SF
, et al;
United Kingdom National Cancer Research Institute
.
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
.
J Clin Oncol
.
2014
;
32
(
27
):
3059
-
3068
.
11.
Shah
Nirav N
,
Johnson
Bryon D
,
Schneider
Dina
, et al
.
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
.
Nat Med
.
2020
;
26
(
10
):
1569
-
1575
.
12.
Bezerra
ED
,
Gauthier
J
,
Hirayama
AV
, et al
.
Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells [abstract]
.
Blood
.
2019
;
134
(
suppl 1
). Abstract 201.
13.
Advani
RH
,
Lebovic
D
,
Chen
A
, et al
.
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
.
Clin Cancer Res
.
2017
;
23
(
5
):
1167
-
1176
.
14.
Ramakrishna
S
,
Highfill
SL
,
Walsh
Z
, et al
.
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
.
Clin Cancer Res
.
2019
;
25
(
17
):
5329
-
5341
.
15.
Schuster
SJ
,
Bishop
MR
,
Tam
CS
, et al;
JULIET Investigators
.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
.
N Engl J Med
.
2019
;
380
(
1
):
45
-
56
.
16.
Turtle
CJ
,
Hanafi
L-A
,
Berger
C
, et al
.
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells
.
Sci Transl Med
.
2016
;
8
(
355
):
355ra116
.
17.
Kochenderfer
JN
,
Somerville
RPT
,
Lu
T
, et al
.
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
.
J Clin Oncol
.
2017
;
35
(
16
):
1803
-
1813
.
18.
Fraietta
JA
,
Lacey
SF
,
Orlando
EJ
, et al
.
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
.
Nat Med
.
2018
;
24
(
5
):
563
-
571
.
19.
Spiegel
JY
,
Sahaf
B
,
Hossain
N
, et al
.
Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma [abstract]
.
Blood
.
2018
;
132
(
suppl 1
). Abstract 576.
20.
Hay
KA
,
Hanafi
L-A
,
Li
D
, et al
.
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
.
Blood
.
2017
;
130
(
21
):
2295
-
2306
.
21.
Shalabi
H
,
Wolters
PL
,
Martin
S
, et al
.
Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy
.
J Immunother
.
2018
;
41
(
7
):
350
-
358
.
22.
Blaeschke
F
,
Stenger
D
,
Kaeuferle
T
, et al
.
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
.
Cancer Immunol Immunother
.
2018
;
67
(
7
):
1053
-
1066
.
23.
Xu
Y
,
Zhang
M
,
Ramos
CA
, et al
.
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
.
Blood
.
2014
;
123
(
24
):
3750
-
3759
.
You do not currently have access to this content.

Sign in via your Institution

Sign In